Snapshot from Sep 20, 2026 at 07:00 UTC. For live data and tracking: View Live
Business Series B financing

NovaGo Therapeutics closes USD 30M Series B

Analysis based on 9 articles · First reported Jul 20, 2026 · Last updated Sep 02, 2026

Sentiment
40
Attention
2
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The financing provides NovaGo with capital to advance its lead candidate into a pivotal proof-of-concept study, potentially accelerating development of a first-in-class regenerative therapy for spinal cord injury. For investors, the participation of established biopharma Neurimmune and venture fund Pureos signals confidence in the science, likely positively impacting sentiment for NovaGo and its backers.

Biotechnology Pharmaceuticals Medical research

NovaGo Therapeutics AG, a clinical-stage biotechnology company developing anti-Nogo-A biologics for central nervous system diseases, announced the successful completion of a CHF 24 million (USD 30 million) Series B financing round. The round was led by Neurimmune and Pureos Bioventures, with participation from existing and new investors. The equity financing is complemented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life. Proceeds will be used to advance NovaGo's lead program into a proof-of-concept study in patients with acute spinal cord injury, a randomized, double-blind trial enrolling 120 patients across sites in Germany, Spain, and Switzerland. NovaGo's approach targets Nogo-A, a protein that inhibits nerve fiber regeneration, aiming to enable functional recovery. The company highlighted promising Phase 1 results with NG004 and the high unmet medical need in spinal cord injury, where no approved regenerative treatments exist.

100 NovaGo Therapeutics closed Series B financing
90 Neurimmune led financing round NovaGo Therapeutics
90 Pureos Bioventures led financing round NovaGo Therapeutics
70 Swiss Paraplegic Foundation provided non-dilutive funding NovaGo Therapeutics
70 Wings for Life provided non-dilutive funding NovaGo Therapeutics
priv
NovaGo is the central entity, closing a CHF 24 million Series B round to fund its proof-of-concept study in acute spinal cord injury. This financing strengthens its balance sheet and advances its lead program toward clinical validation.
Importance 100.0 Sentiment 70.0
priv
Neurimmune co-led the financing and is a strategic partner, having discovered the anti-Nogo-A antibody NG004. Its involvement validates the science and deepens its stake in NovaGo's success.
Importance 80.0 Sentiment 60.0
priv
Pureos co-led the round, providing capital and strategic support. The investment aligns with its focus on innovative drug development and could yield returns if NovaGo's therapy succeeds.
Importance 70.0 Sentiment 55.0
ngo
The foundation provided non-dilutive funding, supporting the trial without taking equity. Its backing underscores the potential patient benefit and may enhance its reputation.
Importance 50.0 Sentiment 45.0
ngo
Wings for Life contributed non-dilutive funding, further enabling the study. Its support reflects its mission to find a cure for spinal cord injury.
Importance 50.0 Sentiment 45.0
per
As Chief Scientific Officer, Schwab is a key scientific figure behind the Nogo-A approach. His leadership is critical to the program's progress.
Importance 40.0 Sentiment 50.0
per
Nitsch, CEO of Neurimmune and NovaGo board member, helped drive the financing and strategic collaboration. His endorsement adds credibility.
Importance 40.0 Sentiment 50.0
per
Escher, Managing Partner at Pureos, co-led the investment, reflecting Pureos's confidence in NovaGo's potential.
Importance 30.0 Sentiment 45.0
per
Moese, CEO of NovaGo, led the company through the financing and will oversee the upcoming trial.
Importance 30.0 Sentiment 45.0
cnt
Switzerland is the home base of NovaGo and a trial site, benefiting from biotech innovation and potential economic gains.
Importance 30.0 Sentiment 40.0
cnt
Germany is a trial site, providing clinical infrastructure and potential healthcare benefits.
Importance 20.0 Sentiment 35.0
cnt
Spain is a trial site, contributing to the study's international scope.
Importance 20.0 Sentiment 35.0
curr
The financing is denominated in Switzerland — Swiss francs, reflecting the currency's role in the transaction.
Importance 10.0 Sentiment 30.0
curr
The USD equivalent is used for international reporting, but the currency itself is not directly impacted.
Importance 10.0 Sentiment 30.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.